Dr Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, leads a webinar on the extended range and next generation CAR-T cells. Watch the full webinar presentation, as well as seven other on-demand webinars, here.
Playfully subtitled Clinical development of CAR-T cells: From “It’s impossible” to “I knew it was a good idea all along”, the presentation was part of Cell & Gene Therapy Manufacturing & Commercialization Digital Week. Dr Levine explains:
"Since the 1990’s, we have conducted clinical trials of gene modified T cells. Chimeric antigen receptor (CAR) T cells targeting CD19 on B cells leukemias and lymphomas have induced durable complete responses in patients who are relapsed or refractory to all other available treatments.
This technology has now undergone global multi-center clinical trials. CAR-T cells targeting new targets in hematologic malignancies and in solid tumors are underway and provide demonstration that it is possible to design immunity at will for therapeutic application."